1. Circulating microRNA signatures associated with disease severity and outcome in COVID-19 patients
- Author
-
Alessandra Giannella, Silvia Riccetti, Alessandro Sinigaglia, Chiara Piubelli, Elisa Razzaboni, Piero Di Battista, Matteo Agostini, Emanuela Dal Molin, Riccardo Manganelli, Federico Gobbi, Giulio Ceolotto, and Luisa Barzon
- Subjects
COVID-19 ,microRNA ,biomarkers ,innate immunity ,inflammation ,interferon ,Immunologic diseases. Allergy ,RC581-607 - Abstract
BackgroundSARS-CoV-2 induces a spectrum of clinical conditions ranging from asymptomatic infection to life threatening severe disease. Host microRNAs have been involved in the cytokine storm driven by SARS-CoV-2 infection and proposed as candidate biomarkers for COVID-19.MethodsTo discover signatures of circulating miRNAs associated with COVID-19, disease severity and mortality, small RNA-sequencing was performed on serum samples collected from 89 COVID-19 patients (34 severe, 29 moderate, 26 mild) at hospital admission and from 45 healthy controls (HC). To search for possible sources of miRNAs, investigation of differentially expressed (DE) miRNAs in relevant human cell types in vitro.ResultsCOVID-19 patients showed upregulation of miRNAs associated with lung disease, vascular damage and inflammation and downregulation of miRNAs that inhibit pro-inflammatory cytokines and chemokines, angiogenesis, and stress response. Compared with mild/moderate disease, patients with severe COVID-19 had a miRNA signature indicating a profound impairment of innate and adaptive immune responses, inflammation, lung fibrosis and heart failure. A subset of the DE miRNAs predicted mortality. In particular, a combination of high serum miR-22-3p and miR-21-5p, which target antiviral response genes, and low miR-224-5p and miR-155-5p, targeting pro-inflammatory factors, discriminated severe from mild/moderate COVID-19 (AUROC 0.88, 95% CI 0.80-0.95, p
- Published
- 2022
- Full Text
- View/download PDF